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Prostate cancer (PC) remains a cause of death worldwide. Here we investigate whether a single microfocus of PC at the biopsy
(graded as Gleason 6 or less, ≤5% occupancy) and the PSA <10 ng/mL can define the archetype of low-risk prostate disease. 4500
consecutive patients were enrolled. Among them, 134 patients with a single micro-focus of PC were followed up, and the parame-
ters influencing the biochemical relapse (BR) were analysed. Out of 134 patients, 94 had clinically significant disease, specifically
in 74.26% of the patients with PSA <10 ng/mL. Positive surgical margins and the extracapsular invasion were found in 29.1% and
51.4% patients, respectively. BR was observed in 29.6% of the patients. Cox regression evidenced a correlation between the BR and
Gleason grade at the retropubic radical prostatectomy (RRP), capsular invasion, and the presence of positive surgical margins. Mul-
tivariate regression analysis showed a statistically significant correlation between the presence of surgical margins at the RRP and
BR. Considering a single micro-focus of PC at the biopsy and PSA serum level<10 ng/mL, clinically significant disease was found in
74.26% patients and only positive surgical margins are useful for predicting the BR.
1. Introduction
Prostate cancer (PC) remains the most common cancer in
men, and its prevalence in men aged >50 years has been
estimated to be as high as 40% [1]. PC still represents the
third leading cause of male cancer-related death, after lung
and colorectal cancer [2], but the majority of cases are
nonlethal [3]. Although it is true that radical treatment signi-
ficantly decreases the risk of death from PC, it is also true
that 19 men need to be treated to benefit one man [4, 5]. This
arises from the prostate-specific antigen (PSA) screening Era,
although the helpfulness of PSA screening still remains
debated.
Andriole et al. report no mortality benefit from com-
bined screening with PSA testing and digital rectal examina-
tion (DRE) during a median follow up of 11 years [6], while
Schröder et al. [7] report that PSA screening without DRE
is associated with a 20% relative reduction in the death rate
from PC at a median followup of 9 years.
However, it remains indubitable that the combined use
of PSA and transrectal ultrasound-guided needle biopsy as
screening procedure has diagnosed an increasing number of
PC, overall at an earlier stage (i.e., low PSA value, grade, and
tumour volume) [8].
This has generated several doubts on the risks of
overdiagnosis and overtreatment of insignificant neoplastic
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diseases. It is unclear whether all patients diagnosed with PC
warrant radical treatment or may benefit from delayed inter-
vention following active surveillance. The challenge remains
to distinguish accurately those potentially dangerous lesions
from nontreating cancers.
The above considerations have led to categorize patients
with PC in three groups with low or insignificant, intermedi-
ate, and high risk.
During the last years, different definitions of insignificant
or low-risk PC have been proposed [9]. However, all of them
have highlighted limits in patient stratification. Using the
more restrictive definition, low-risk PC might be defined as
that detected in patients with PSA <10 ng/mL, stable PSA
kinetics, Gleason grade≤6, and Clinical Stage T1/T2a [10]. It
is known that patients with low-risk cancer have 10-year PC
survival rates in excess of 99% [10, 11], while is still uncertain
whether intervention improves a longer survival time. To
avoid that patients will undergo radical treatment for pre-
sumed clinically insignificant PC, active surveillance has been
applied as an alternative option to an immediate treatment
[9–16]. According to Stamey et al., a tumour with a volume
<0.5 mL and a Gleason score <7 would not be life threaten-
ing, because such PC have a long doubling time [16]. On the
basis of these premises in the category of low-risk PC, a sub-
group of patients with a diagnosis of a single microfocus
(defined as ≤5% occupancy in 1 biopsy core with Gleason
grade ≤6), PSA <10 ng/mL and clinical stage T1c, represents
the archetype of low-risk PC. Despite various definitions
of “cancerous microfocus,” have been proposed, the risk of
finding clinically insignificant disease at successive RRP
varies from about 9% to 40% [17–20].
In addition, Thong et al. have found an association
between the presence of a single microfocus at biopsy and BR
after robotic prostatectomy in about 3% of patients [21].
The above considerations raise the following questions:
are the actual parameters for predicting the real biological
impact of the disease really helpful? And, is the pathological
definition of insignificant PC disease still valid? [22–25].
Here we correlated the detection of a tumoural micro-
focus at even repeat prostatic biopsy and the presence of
clinically significant disease detected after RRP and patient’s
followup. The definition of clinically significant disease has
been reevaluated in the light of the biochemical relapse (BR).
Additionally, we verified whether some preoperative and
pathological parameters could be helpful in identifying sub-
groups of patients who may need more or less aggressive
and/or timely appropriate treatment.
2. Materials and Methods
2.1. Patients. 4500 consecutive patients who underwent sex-
tant prostate biopsies at the IRCCS Istituto Clinico Humani-
tas, Rozzano, Milan, Italy and at the Fidenza Hospital, Parma,
Italy between January 2000 and September 2008 were
enrolled in the study. All of them had high preoperative PSA
levels (>2.5 ng/mL) and/or abnormal results upon digital
rectal exploration (DRE).
Their PSA density (ultrasonography PSAD) and f /t
ratios were tested and monitored overtime, and the volume
of their prostate glands was estimated ultrasonographically
using the elliptical method [26]. None of the patients had
received neoadjuvant therapy or treatment with 5-alpha
reductase inhibitors. All of the patients were clinically fol-
lowed (including DRE and PSA determinations) every six
months. BR was defined as detectable PSA level (>0.2 ng/mL)
with increase of this value during the followup. All of the
patients underwent ultrasound-guided modified sextant
prostatic needle biopsies under local anaesthesia induced by
a single dose of lidocaine [25]. The mean number of biopsy
cores per procedure was 13 (range: 11–20 biopsy cores), and
they always included the transitional zone, apex, and lateral
part, as well as the midmedial, midlateral, basal, and anterior
zones [27].
2.2. Histological Analysis. Radical retropubic prostatectomy
(RRP) specimens were weighed, fixed in 10% formalin,
embedded in paraffin, serially cut at 3 μm intervals, and sub-
sequently histochemically stained with a freshly made
haematoxylin and eosin solution for the microscopy obser-
vation by the same uropathologist (PC). For each patient
anatomo-clinical parameters, including the percentage of
neoplastic disease, Gleason score, capsular invasion, and
surgical margins, were evaluated.
A microfocus of prostate adenocarcinoma was defined as
≤5% occupancy of 1 biopsy with Gleason grade ≤6 [22, 23,
26, 27]. Patients with Gleason grade >7, and/or with tumour
foci in more than one biopsy core, as well as those with
a diagnosis of high-grade prostatic intraepithelial neoplasm
(PIN) or atypical small acinar proliferation (ASAP) were
excluded by the study.
Clinically insignificant prostate carcinoma was defined as
the presence of a tumour in 5% of the glands with a Gleason
grade <7 [17, 24].
2.3. Statistical Analysis. Categorical data are presented as
absolute frequency and percentage proportion; continuous
data are presented as median and range. Parametric and
nonparametric tests were used as appropriate in order to
evaluate the significance of differences in variables’ distribu-
tion (t-test, Fisher’s exact test, Wilcoxon’s rank-sum test, and
Pearson’s χ2). Survival analysis was carried out according to
the Kaplan-Meier method and the Cox proportional hazards
regression model to evaluate prognostic factors related to the
biochemical relapse. A significance level of 5% was adopted.
3. Results
The needle biopsies showed that 194 of 4500 (4.3%) patients
had a single microfocus of adenocarcinoma. 134 out of 194
(67%) patients who underwent RRP nerve sparing (PSA
6.3 ng/mL (range: 2.1–33 ng/mL), f /t ratio 15% (range: 0.5–
44%), and PSAD 0.12 (range: 0.05-06) were adequately
informed about the available diagnostic and therapeutic
possibilities, as well as the published criteria regarding the
definition of clinically insignificant disease. 11 out of 134
(8%) patients were to undergo radiotherapy and 49 out of
194 (25%) were to undergo active surveillance. 94 out of
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134 patients (70.15%) were diagnosed as affected by clinical
significant disease, while 40 (29.85%) patients had clinical
insignificant disease at the successive RRP.
101 out of 134 patients (75.37%) had PSA <10 ng/mL.
In 75 (74.26%) patients a clinically significant disease was
found, while in 26 (25.74%) a clinically nonsignificant dis-
ease was detected at the successive radical prostatectomy.
33 (24.63%) patients had PSA >10 ng/mL. In 19
(57.58%) patients a clinically significant disease was found,
while in 14 (42.42%) patients a clinically non-significant dis-
ease at the successive radical prostatectomy was detected. No
statistically significant differences were found between the
percentages of clinically significant disease (P = 0.069) and
f /t ratio (P = 0.98). In contrast, a higher PSAD was found
in patients with PSA >10 ng/mL (P ≤ 0.001).
39 (29.1%) patients showed positive surgical margins. In
34 out of 101 (33.66%) patients with PSA <10 ng/mL had
positive surgical margins, while 5 (15.15%) patients with
PSA >10 ng/mL had positive surgical margins. Incidentally,
the percentage of positive surgical margins was found statis-
tically significant in the group of patients with PSA <10 ng/
mL (P = 0.042).
69 out of 134 (51.49%) patients had capsular invasion. In
54/101 (53.47%) patients with PSA <10 ng/mL were found
capsular invasion. In 15/33 (45.45%) of patients with PSA
>10 ng/mL had capsular invasion. No statistically significant
differences were found between two groups with regard to
capsular invasion at the successive RRP (P = 0.424).
The following pathological stages have been scored: 2
(1.49%) pT0; 32 (23.88%) pT2aN0; 28 (20.90%) pT2bN0;
47 (35.07%) pT2cN0; 20 (14.93%) pT3aN0 and 5 (3.73%)
pT3bN0. Classifying the patients on the basis of the PSA
behaviour, no statistically significant differences have been
found, although a prevalence of the stage pT2cN0. No statis-
tically significant differences have also been found between
patients with a Gleason score ≤6 and those ≥7 (P = 0.202).
We divided the patients to two groups: 87 (64.93%) of
them underwent RRP after a first needle biopsy with a micro-
focus of adenocarcinoma (group 1) and 47 patients (35.07%)
underwent RRP after a first biopsy had shown a microfocus
of adenocarcinoma and a second had led to the identification
of a tumour >5% occupancy of 1 biopsy with Gleason grade
>6, or with multiple adenocarcinoma foci (group 2).
Group 1 included 87 (64.93%) patients with a mean PSA
equal to 7 ng/mL (range: 2.6–33 ng/mL); f /t ratio 13.05
(range: 4–44); PSAD 0.14 (range: 0.046–0.6). In 65 (74.71%)
of them a clinically significant disease has been found, while
in 22 patients (25.29%) the disease was clinically insignifi-
cant.
Group 2 included 47 (35.07%) patients with a mean PSA
equal to 6.1 ng/mL (range: 2.6–25 ng/mL), f /t ratio 17.5
(range: 0.5–40), and PSAD 0.12 (range: 0.051–0.384). In 29
patients (61.70%) a clinically significant disease has been
found, while in 18 (38.30%) patients the disease was clini-
cally insignificant.
There were no statistically significant differences between
two groups with respect to the percentage of clinically signi-
ficant disease (P = 0.116), PSA levels (P = 0.407), and f /t
ratio (P = 0.169). PSAD was higher in Group 1 (P = 0.013).
Additionally, there were no statistically significant differ-
ences between two groups with respect to the Gleason grade
and pathological stage, although two patients with stage pT0
belong to group 1.
We analysed the percentage of BR after patient followup
considering all the clinical, biochemical and pathological
stage to highlight any positive prognostic factors.
118 out of 134 (88.06%) patients have been analysed. 2
patients died during the followup for other causes (1 colorec-
tal cancer and 1 pancreatic cancer), while 14 patients were
lost. The median followup was 28 months (range: 3.7–96
months). 35 out of 118 (29.6%) patients had BR.
Using the Cox regression, the following parameters were
found statistically significant with the biochemical relapse:
Gleason score (HR = 2.94, P = 0.009), the capsular invasion
(HR = 3.56, P = 0.006), and positive surgical margins (HR =
6, P < 0.001).
In contrast, there was no statistical significance between
BR and PSA value (P = 0.974), pathological stage (P =
0.168), definition of clinically significant disease (P = 0.070),
confirm at rebiopsy (Group 1 versus Group 2) (P = 0.860),
f /t ratio (P = 0.625), and PSAD (P = 0.318). We therefore,
evaluated the effect of significant variables taken together
(multivariate Cox regression) and found that only the pres-
ence of positive surgical margins is a predictive factor for the
BR (P = 0.006).
4. Discussion
Approximately 32% of male Caucasians aged more than 50
years have PC at autopsy. The lifetime risk of developing PC
in the United States is 1 in 6, and the lifetime risk of death due
to metastatic PC is 1 in 30 [28]. The advent of PSA testing
has changed our understanding of the natural history of the
prostatic disease [16–30], but the widespread use of repeated
and extended biopsies has increased the rate of patients with
apparently clinically insignificant disease. This problem, in
epidemiologic term, is defined as the diagnosis of cancer that
will not be diagnosed clinically during life [31].
The above considerations demonstrate the difficulty to
correctly select the patients to be treated (i.e., radical prosta-
tectomy, radio-therapy, and active surveillance) and how to
define the criteria of risk of progression of the neoplastic
disease.
Within the low-risk group there is a subgroup of patients
with a single microfocus of PC at biopsy with PSA<10 ng/mL
which, according to the existing parameters, represents the
archetype of the disease at low-risk and therefore less than
that should provide for a radical treatment.
Current data on the proportion of clinically significant
disease in the presence of a microfocus remain contradictory,
and the risk of finding clinically insignificant disease varies
from about 9% to 40% [17–23, 26–33].
In our retrospective study, we selected 134 patients
who underwent nerve-sparing RRP after the histological
diagnosis of a single microfocus of PC, associated or not with
a second confirmation of disease at repeat biopsy. Clinically
significant disease was found in 70.15% patients and more
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specifically in 74.26% of patients with PSA <10 ng/mL and
57.58% in those with PSA >10 ng/mL (P = 0.069).
We examined several clinical and epidemiological para-
meters including clinical stage, f /t ratio, PSAD, and age, and
pathological parameters such as surgical margins, Gleason
grade, pathological stage, and capsular invasion, to assess
whether the group with the lower-risk disease corresponded
to a minor impact. Surprisingly, we found a statistically signi-
ficant difference between the group with PSA levels <10 ng/
mL and that with PSA levels >10 ng/mL with respect to posi-
tive margins being higher in the group with PSA <10 ng/mL.
With regard to capsular invasion, the pathological stage and
Gleason score there were not observed statistically significant
differences between the two groups.
We then analysed in 35% of patients the possible impact
of histological confirmation at rebiopsy although we found
that it did give not additional information and did not reduce
the risk of clinically significant disease as confirmed at the
subsequent RRP.
Finally, we evaluated the followup of these patients and
have found that none of the patients died from PC. Although
the period of observation is limited as much as 29.6% of
patients showed a BR. Using the Cox regression we found a
statistical significance among the BR and the Gleason score
(HR = 2.94, P = 0.009), the capsular invasion (HR = 3.56,
P = 0.006), and the presence of positive surgical margins
(HR = 6, P < 0.001). In contrast, there was no statistical
significance with PSA level, pathological stage, definition of
clinically significant disease, confirm at rebiopsy, f /t ratio,
and PSAD.
Then, when we examined the multivariate Cox regression
we found that only the presence of positive surgical margins
appears to be the factor related to the BR. On the basis of the
above results emerges that the predictive values we investigate
have not proved helpful to carefully selected patients.
There is an urgent need to understand the significance of
insignificant PC [24]. In a study by Allan et al. 54 patients
were identified with a Gleason grade 6 single microfocus
of PC on prostate needle biopsy [22]. While twothirds of
the patients had potentially insignificant tumours at radical
prostatectomy, a third of their cohort harboured clinically
significant tumours exceeding the actual criteria (i.e., Glea-
son score≤6, organ confined, and a volume <0.5 cm3). Allan
et al. also reported that a PSAD <0.15 ng/mL correlated with
potentially insignificant tumours at the RRP [22]. In our
study, the PSAD, obtained by ultrasonography, it has not
proved useful to select patients because the relationship with
BR is mainly due to the presence of positive margins and thus
the seat of the tumour and pathological stage or size of the
prostate for equal PSA levels.
In a more recent study similar findings correspond to
that observation since 22% of the cases were upstaged to
pT3 and/or upgraded to Gleason score 7 or greater [21]. In
our study 74% of the patients showed at the RRP a clinically
significant PC (pT2b + pT2c + pT3a + pT3b).
The real problem is the excess of confidence on the
staging possibilities of extensive prostate biopsy. The primary
outcome of the prostate biopsy sampling for diagnosing PC
is the increase of the number of biopsy cores to increase the
diagnostic sensitivity. The biopsy has a quality value. The
turn in a prognostic value of a sampling percentage is not
immediate.
In fact in a cohort studied by Sheridan et al. men with
low-risk prostate cancer, defined as Gleason grade ≤6, fewer
than 3 positive cores with no cores occupied by greater than
50% of cancer and clinical PSAD less than 0.15, who were
undergoing active surveillance were at 19% risk of upgrading
on subsequent biopsies [34]. Most tumours were upgraded
within 24 months of the initial diagnosis, suggesting that a
higher-grade tumour was not sampled in the original biopsy.
Observations in the study of Thong [21] support these
findings because 18% of cases were upgraded at surgery.
Therefore needle biopsy alone is not sufficiently reliably to
differentiate tumours that are clinically insignificant and
those that are upstaged or upgraded to clinically significant
tumours, which more clearly warrant definitive treatment.
Likely to the PSA we have not shown statistically signif-
icant differences in the proportion of clinically significant
disease among the group of patients with PSA <10 ng/mL
and those with PSA >10 ng/mL. Moreover, the fact that the
group of patients with PSA >10 ng/mL, that is, theoretically
with a more aggressive disease showed a lower percentage of
positive surgical margins compared to the group of patients
with PSA <10 ng/mL. These results all confirm the low
predictive sensitivity of PSA in the patient groups analysed.
Although the claimed importance of rebiopsy [20], we here
have not shown statistically significant differences regarding
the proportion of recognized clinically significant disease, the
Gleason score, and pathological stage disease when com-
pared to patients not undergoing rebiopsy, and more impor-
tantly between the two groups with respect to BR.
Regarding the resumption of BR we have observed that
this was related to the Gleason grade, capsular invasion, and
positive surgical margins. But by performing a multivari-
ate Cox regression only the positive surgical margins were
related to BR.
Importantly in all cases investigated in our study, in
addition to that PSA and PSAD were not indicative nor the
definition of disease is not clinically significant, which is
based on the rate of disease and not on the premises. Smaller
cancers but closer to the margin is more risky for the resump-
tion of the disease. Thong et al. have reported that 3% of
recovery biochemical disease in a group of patients under-
going robotic RP after detection of a microfocus at biopsy
[21].
The percentage of biochemical relapse appears lower
than that found in our study (3% versus 29.6%).
In comparison to the study of Thong et al. the percentage
of positive surgical margins is unquestionably more elevated.
By analysing only the patients staged as pT2, we detected a
percentage of 19.6% of cases with positive margins. Although
the value remains high a variable range comprises between
2% and 49% has been reported [35]. Comparing our data
with those reported by Ojea Calvo et al. and other authors
[35], we found a percentage of positive surgical margins
equal to 9.3% versus 6.9 for pT2a cases and 28.5% versus
18.6% for pT2b cases. In literature it emerges that today it
is not possible to foresee result with certainty and therefore
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to avoid to produce positive margins [35]. Therefore the
difference with the percentages published by Thong et al.
can mainly result from the population in examination, the
histopathological examination, or from the actual surgical
procedures. With regard to the BR, our results agree to those
of Gardner et al. that underline, with a followup of 24
months, the 6% of resumption biochemistry for microfocus
with 6% of positive margins [17]. This difference can be
justified on the basis of the shorter followup (12.2 months,
range: 1.2–53 versus 28 months, range: 3.7–96 months), or
to the percentage of positive margins (6% versus 29.1%).
It should be underlined that a limit of our study consists,
although great in comparison to other published studies, in
the time of followup.
5. Conclusions
We can conclude that there exists a nonclinically significant
disease; it is indubitable that we know an overtreatment of
an unnecessarily large group of patients, but this is mainly
due to the scarce knowledge on the complexity underlying
the progression of the tumoral prostatic disease, the multi-
scale causality that is intrinsically determining the dynamical
behaviour of PC, and the fact that actual parameters do not
recognize the risk of disease progression and are incapable to
accurately select patients to be treated. Our results show that,
to date, the predictive value that we look in hope to select
patients may even be misleading; making choice of treatment
over another lead to error, and therefore only the introduc-
tion and development of new and different predictive values
can overcome this impasse. While remaining clear the axiom
that only a small fraction of patients with PC dies because
of disease and act on all over would entail an unacceptable
treatment, and we are not yet able to identify with certainty
those who may simply be observed. From our experience, in
fact, the detection of a single microfocus in one biopsy with
Gleason grade ≤6 and PSA <10 ng/mL cannot be identified
as a sufficient parameter to define an indolent disease.
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